Science & Pipeline

Genvara specializes in identifying common genetic variation that can be therapeutically targeted (“pharmacogenetics”) in cardiovascular disorders. Our basic and clinical research programs focus on human cardiac systems in order to provide a direct path from discovery to clinical application, utilizing our decades-long experience in molecular genetics, molecular pharmacology, clinical trials and drug development. Our pharmacogenetic, precision therapeutic approach, on which Genvara was founded, is to target haplotypes that contain multiple polymorphisms in protein drug targets, since it is protein haplotypes that dictate function. This has long been recommended as the preferred approach to pharmacogenetics, but has yet to be realized. We are poised to embark on a single, modest size (N=350) Phase 3 trial with our lead compound (Gencaro™) that targets a combination of β1- and β2-adrenergic receptor haplotypes, which based on extensive interactions with FDA will be the basis for approval in the indication of prevention of atrial fibrillation in patients with heart failure.